Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
NY Gov Signs AI Safety Bill New York Gov. Kathy Hochul (D) signed legislation ( AB 6453 / SB 6953 ) establishing safety and reporting requirements for major developers of so-called frontier artificial...
For two years running , we’ve opened our annual story predicting the top issues for state legislators in the coming year by noting just how tense and uncertain things are, with the war in Ukraine...
States Sue to Block H-1B Visa Fee The attorneys general of 20 states, led by California and Massachusetts, filed a federal lawsuit aimed at blocking the Trump administration’s new $100,000 fee...
Florida House Speaker Daniel Perez (R) unveiled a two-bill healthcare package aimed at aligning the state with President Trump’s new federal framework. HB 693 would tighten eligibility for Medicaid...
President Donald Trump has waded into one of the most pressing and prevalent issues in state capitols these days: regulating artificial intelligence. In early December, the president said on his Truth...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.